#Vigabatrin Market Share | Explore Tumblr posts and blogs

tmr123123 · 3 years ago

Text

Epilepsy Drugs Market Report Explored in Latest Research 2021-2030

Global EPILEPSY DRUGS MARKET Growth 2021-2027 was just released by Trends Market Research. The report offers an in-depth examination of the main elements that can assist well-known firms in the sector in developing effective future action plans. Market revenue and market size are the two primary parameters analysed in this study. In the projected period 2021-2027, the market research offers key information such as market share, market size, and growth rate. The research offers insights into market developments, trends, and supply and demand changes in a variety of global regions.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.trendsmarketresearch.com/report/sample/3863

The research offers insights into market developments, trends, and supply and demand changes in a variety of global regions like:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The study examines the worldwide EPILEPSY DRUGS MARKET -supported product type, application, and end-use across a variety of nations.

Key Epilepsy Drugs Covered in the Report are as follows:

Vimpat(Lacosamide) 2. Keppra(Levetiracetam) 3. Briviact(Brivaracetam) 4. Lamictal(Lamotrigine) 5. Neurontin (Gabapentin) 6. Depakine (Sodium Valproate) 7. Sabril (Vigabatrin) 8. Onfi(Clobazam) 9. Fycompa(Perampanel) 10. Inovelon/Banzel(Rufinamide) 11. Zonegran (Zonisamide) 12. Zebinix (Eslicarbazepine Acetate)

Direct Purchase this Market Research Report Now @ https://www.trendsmarketresearch.com/checkout/3863/Single

The report displays the stated data in the form of pie diagrams, line graphs, and different updates that isolate the real data. The study examines the market in depth, covering dynamic growth determinants, limitations, challenges, and possibilities.

It also includes a study of important market participants and their most current market strategies in order to assist new market entrants, stakeholders, and shareholders in developing lucrative company plans.

Major players in the market include:

UCB 2. EISAI 3. Pfizer 4. Sanofi 5. Lundbeck

The research examines the various tactics used by market participants to retain their position in the worldwide EPILEPSY DRUGS MARKET.

Get Discount On The Purchase Of This Report @ https://www.trendsmarketresearch.com/report/discount/3863

0 notes

medicaldevicetech · 4 years ago

Text

Post-operative Pain Management Market Outlook- Size, share, Report and Demand

Post-operative Pain Management Market Analysis

The global post-operative pain management market is predicted to grow at a 5.4% CAGR between 2017-2023, reveals the latest Market Research Future (MRFR) report. Post-operative pain is unpleasant and annoying, which, if not treated correctly and on time, can result in chronic pain, which may last for months. Post-operative pain is a common adverse outcome owing to physical distress, prolonged hospital stays, and the growing incidence of readmissions of patients after surgery. Post-operative pain management helps in minimizing patient discomfort, facilitating early mobilization, functional recovery along with preventing acute pain turning into chronic pain. Besides, it also helps to lessen the possibility of pulmonary, cardiac, and neuropathic pain complications, low cost of care, and cut down the risk of thrombosis.

Get Latest Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1246

Various factors are propelling the post-operative pain management market growth. These factors, as per the new Market Research Future (MRFR) report, include growing incidence of diseases that need surgical treatments, development of novel drugs for quick pain relief, increased R&D activities to develop high-quality post-operative pain management solutions with minimum side effects, increasing prevalence of various chronic diseases such as cardiovascular diseases, renal diseases, cancer, and others, and increase in geriatric population. Additional factors pushing market growth include the increasing number of cancer patients and burgeoning demand for pain control devices and drugs.

On the flip side, poor primary health care services, especially in underdeveloped regions and complications related to overdose of pain management drugs, are factors that may impede the post-operative pain management market growth over the forecast period.

Market Segmentation

The MRFR report provides an all-inclusive segmental analysis of the Post Operative Pain Management Market Growth on the basis of target area, application, product, and pain type.

Based on pain type, the post-operative pain management market is segmented into severe pain, moderate pain, and acute pain.

Based on the product, the post-operative pain management market is segmented into opioids, COX-2 inhibitors, antiepileptic drugs, non-steroidal anti-inflammatory drugs, and other analgesics.

Based on the application, the post-operative pain management market is segmented into migraine, musculoskeletal pain, neuropathic pain, arthritic pain, cancer pain, and others. Of these, the cancer pain segment will have the largest share in the market over the forecast period.

Based on target area, the global post-operative pain management market is segmented into arms, hand, legs, back, and others.

Regional Analysis

By region, the post-operative pain management market report covers the latest trends and growth opportunities across the Asia Pacific (APAC), the Americas, Europe, and the Middle East and Africa. Of these, the Americas will dominate the market over the forecast period. This is chiefly on account of the presence of well-developed healthcare infrastructure in the region and the huge patient pool undergoing surgical procedures.

The post-operative pain management market in Europe is predicted to have the second-largest share in the market over the forecast period. This is chiefly on account of the increasing R&D activities for the launch of new drugs with minimal side-effects.

The post-operative pain management market in the APAC region is predicted to grow at the fastest pace over the forecast period. This is chiefly on account of the growing incidence of chronic diseases that needs surgical treatment coupled with an increase in the geriatric population.

The global post-operative pain management market in the MEA is predicted to have steady growth over the forecast period. This is chiefly on account of poor primary health care services, especially in the region’s underdeveloped areas and lack of awareness.

Key Players

Prominent players profiled in the post-operative pain management market report include Valeant Pharmaceuticals International Inc. (Canada), Baxter International Inc. (the US), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline Plc. (the UK), Forest Laboratories Inc. (the US), Endo Pharmaceuticals Plc. (the US), Purdue Pharma (the US), Johnson & Johnson (the US), Pfizer (the US), Eli Lilly (the US), and Teva Pharmaceutical Industries Ltd. (Israel). Key players have incorporated several strategies to create a niche in the market, such as research and development activities, joint ventures, expansions, product launches, and more.

Industry News

August 2019: Dr. Reddy’s Laboratories has recently launched generic anti-epileptic Vigabatrin powder in the US market for oral solution.

Read more @ https://www.marketresearchfuture.com/reports/post-operative-pain-management-market-1246

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India +1 646 845 9312 Email: [email protected]

NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

#Post-operative Pain Management Market Analysis

0 notes

maximizenetwork · 4 years ago

Text

Global Aicardi Syndrome Market- Industry Analysis and forecast 2019 – 2027

Global Aicardi Syndrome Market size was valued at US$ XX Bn. in 2019 and the total revenue is expected to grow at 3.4% through 2019 to 2027, reaching nearly US$ XX Bn.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Aicardi syndrome is a disorder that arises almost exclusively in newborn girls. The several identified cases of newborn girls with aicardi syndrome are almost 300 to 500 globally. People suffering from Aicardi syndrome either do not have a tissue in the right and left halves of the brain or the tissue may be underdeveloped..

The MMR report covers all the trends and technologies playing a significant role in the growth of the aicardi syndrome market over the forecast period. It highlights the opportunities, challenges, drivers, and restraints expected to influence the market growth during 2019-2027. The global market for aicardi syndrome is expected to experience a lucrative growth rate during 2019-2027 thanks to technological advancements in the medical industry and rising prevalence of rare disorders. However, the lack of awareness in the emerging regions may be restraining factor for the growth of the aicardi syndrome market over 2019-2027.

As per the Aicardi Syndrome Foundation, the incidence of Aicardi syndrome is projected to be nearly 1 in every 100000 births. The particular cause of the disorder is unknown. Though, it is considered to be caused by a first-time mutation in the child’s genes. Sometimes, various cases of Aicardi syndrome remain undiagnosed due to the limited access to good medical care in the less developed economies or early death.

Based on the treatment, the seizure medication segment dominated the aicardi syndrome market, with market size of US$ XX Mn in 2019 and to reach US$ XX Mn by 2027, with a CAGR of XX.55%. Most children are not applicants for brain surgery because of many areas of epileptogenesis. Likewise, the report covers the segments in the aicardi syndrome market such as diagnosis, treatment, and end-user.

Demographic and clinical data from Aicardi syndrome girls:

Global Aicardi Syndrome Market1

The report offers a brief analysis of the major regions in the aicardi syndrome market, namely, APAC, Europe, North America, Latin America, and the MEA. North America is expected to continue to hold the largest XX% share in aicardi syndrome market thanks to the growing healthcare expenditure offers a promising background for pharmaceutical enterprises. As per the CDC (Centers for Disease Control and Prevention), in 2015, total countrywide health expenses were US$ 3.2 trillion. Europe holds the second-largest share in the aicardi syndrome market thanks to the growing R&D funding.

However, the MEA holds the least share of the Aicardi syndrome market because of lack of technical knowledge, poor medical services, and low development in emerging economies in Middle East & Africa.

The competitive landscape section in the Aicardi syndrome market offers a deep dive into the profiles of the leading companies operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the key players having a stronghold in the Aicardi syndrome market.

The objective of the report is to present a comprehensive analysis of the Global Aicardi Syndrome Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Aicardi Syndrome Market dynamics, structure by analyzing the market segments and projects the Global Aicardi Syndrome Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Aicardi Syndrome Market make the report investor’s guide. Scope of the Global Aicardi Syndrome Market

Global Aicardi Syndrome Market, by Diagnosis

• Magnetic Resonance Imaging (MRI) • Eye Examination • Others Global Aicardi Syndrome Market, by Treatment

• Seizure Medication o Vigabatrin o Sodium Valproate o Others • Surgery • Physical Therapy • Occupational Therapy • Speech Therapy • Vision therapy • Others Global Aicardi Syndrome Market, by End-User

• Hospital Clinics • Diagnostic Centers • Others Global Aicardi Syndrome Market, by Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA Key players operating in Global Aicardi Syndrome Market

• Siemens Healthineers • General Electric Company • Koninklijke Philips N.V. • Hitachi, Ltd. • Canon Medical Systems Europe B.V. • Medtronic • Smart Speech Therapy • Therapy Solutions Inc. • Carestream Health • Esaote SpA • Lundbeck • Novartis AG • CryoLife, Inc • Cohera Medical Inc • CSL Behring

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.</p>

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: [email protected] Contact: +919607065656 / +919607195908 Website:www.maximizemarketresearch.com

#Aicardi Syndrome Market Analysis

0 notes

myabhijitr · 5 years ago

Text

Infantile Spasm Treatment Market - Size, Share, Outlook, and Analysis, 2018-2026

The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study.

Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2453

Moreover, the government of Brazil in year 2017 amended its regulatory rules for approving drugs for rare disease. In December 2017, Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA) published Resolution RDC 205/2017, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm.

Key players in the market are focused on launching cost-effective generic drugs, in order to treat infantile spasm and address the critical unmet needs of patients. For instance, in May 2018, Amneal Pharmaceuticals launched vigabatrin for oral solution USP, which is a generic equivalent for Sabril. This is the second generic vigabatrin product available in the market. Aucta Pharmaceuticals and Upsher-Smith Laboratories, LLC launched vigabatrin for oral solution under the brand name Vigadrone in July 2018, which is another generic version of vigabatrin (Sabril).

As of 2018, there were around 5 novel drug candidates in development. 60% of these drugs are in phase III of development, which are expected to enter the market in the near future, thereby offering effective treatment among the fastest growing markets in the world.

Key players operating in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in April 2014, Mallinckrodt Pharmaceuticals acquired Questcor, a company involved in contract manufacturing services. Questcor has FDA approved H.P. Acthar Gel, an injectable drug for 19 indications such as infantile spasm.

Purchase Copy of Infantile Spasm Treatment Report: https://www.coherentmarketinsights.com/insight/buy-now/2453

The global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Anavex Life Sciences Corp., Catalyst Pharmaceuticals, GW Pharmaceuticals plc, and Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics Inc., Etrophin Inc., and Catalystpharma.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#infantile spasm treatment market #infantile spasm treatment market size #infantile spasm treatment market outlook

0 notes

pharmaworldtoday · 6 years ago

Photo

Officials with the FDA today approved the first generic version of vigabatrin 500-mg tablets, which is also sold under the brand name Sabril, a medication used to treat complex partial seizures, according to a press release. Complex partial seizures, also called focal seizures, is a common type of seizure that begins in a specific area of the brain and can affect consciousness. Vigabatrin is indicated as an adjunctive therapy for focal seizures in patients 10 years of age and older who have responded inadequately to several alternative treatments. Sabril, which is marketed by Lundbeck, was approved by the FDA in 2009 in tablet and powder form. The medication includes a boxed warning for the possibility of permanent vision loss. The label also includes warnings for suicidal behavior and ideation, anemia, and abnormal MRI changes, according to the prescribing information. Teva’s newly approved generic version is part of a single shared-system risk evaluation and mitigation strategy program with other drug products containing vigabatrin to ensure safe use of the product. The most common adverse effects associated with vigabatrin tablets include dizziness, fatigue, sleepiness, involuntary eye movement, tremor, blurred vision, memory impairment, weight gain, joint pain, upper respiratory tract infection, aggression, double vision, abnormal coordination, and a confused state. In 2017, the FDA began a list of off-patent, off-exclusivity branded drugs without approved generics, including Sabril, in an effort to advance the development of generic products. “Today’s action demonstrates that there is an open pathway to approving products like this one,” FDA Commissioner Scott Gottlieb, MD, said in the release. According to Dr Gottlieb, the FDA has been focused on new policies aimed at improving the generic review and launch process. #PharmaWorldToday #pharmacyschool #pharmacist #pharmacy #pharmacology #drugs #medicine #medicines #medicinestudent #medstudent #nursingstudent #medstudents #pharmacyrocks #pharmacytech #pharmd #pharmacylife #medical #health #facts #gpatexam https://www.instagram.com/p/Bs59fOShvx_/?utm_source=ig_tumblr_share&igshid=w3wp8utr3gbi

0 notes

shaqibakram · 5 years ago

Text

Global Anti-Epileptic Drugs Market Growth, Trends, Absolute Opportunity and Value Chain 2019-2026

Antiepileptic drug can also be known as anti-seizure drug, developed for asymptomatic and Idiopathic treatment of epilepsy and seizures. Antiepileptic drugs can also be used for the treatment of neuropathic pain. Causes of epilepsy seizures are not defined or undetermined which has led many Antiepileptic drugs approved in the past years. Major factors which causes epilepsy include brain injury, stroke, and substance use disorders. Treatment of epilepsy, antiepileptic drugs or medicines (AEDs) are prescribed based on age of the patient, type of seizures to be treated, and which part of the brain is involved.

Based on Drug Valporic Acid (salt) is anticipated to lead the market during 2019-2026 Valporic Acid segment is expected to hold maximum share in the market during the forecast period due to effective drug structure and its usage in most type of seizures. However, the highest growth rate is predicted to be exhibited by Lacosamide during the forecast period owing to surging adoption of Anti-Epileptic Drugs market among healthcare professionals and patients due to its homogenous structure.

Request for Sample Report- https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/sample-request

North America held the largest market share in global Anti-Epileptic Drugs market in 2018 owing to increasing social awareness, social acceptance, awareness among the population and government and private players inclination on Anti-Epileptic Drugs issues. Rest of the World is predicted to be the attractive regional market in global Anti-Epileptic Drugs market and is likely to show the maximum growth in the next few years.

Various notable players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The Global Anti-Epileptic Drugs Market has been segmented on the basis of spectrum type, drug type, and key geographies. Based on spectrum type, the market comprises of Narrow Spectrum and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide

Request for Customization – https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/request-for-customization

Key questions answered in this research report: • At what pace is the Anti-Epileptic Drugs market growing worldwide? What will be the growth trend in future? • What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the coming years? • What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in global Anti-Epileptic Drugs market? • What are the various application areas and how they are poised to grow?

For Additional Insights, Click to Access Complete Report - https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/

About GMI Research

GMI Research is a market research and consulting firm which provides research-based solutions to business executives and investment professionals so that they can make right business & investment decisions faster based on real facts. We help business leaders through independent fact-based insight, ensuring their business achieve success by beating the competition. GMI Research’s leadership team with extensive experience in research and consulting together with our research and domain expertise creates a strong value proposition to create solutions that addresses our client’s business problems and add significant value to long lasting relationship.

The company provides syndicated research report, customized research, sales enablement research, data analytics and KPO (knowledge process outsourcing) service for Electronics & Semiconductors, Information Communication and Technology, Energy & Power, Healthcare, Automotive, Transportation & Logistics and Chemical industries. Our analysts and consultants who are passionate about research and consulting are recruited from renowned local and global universities and have worked with the leading local and international organizations.

Company Name: GMI RESEARCH

Contact Person: Sarah Nash

Email: [email protected]

Phone: +353 1 442 8820

Address: Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate

City: Dublin

State: Dublin

Country: Ireland

Website: www.gmiresearch.com

#gmiresearch

0 notes

nikitamanwar · 5 years ago

Text

North America held the maximum revenue share in 2018 and it is expected to lead in the forecast period, growing at a CAGR of 3.9% during 2019–2026 -GMI Research

The Global Anti-Epileptic Drugs Market was valued at USD 3,323.0 million in 2018, and is expected to reach USD 4,458.0 million by 2026, growing at a CAGR of 3.8% during 2019–2026. The major driving factors of the anti-epileptic drugs market is the rising awareness about epilepsy and new drug approvals over the past few years. Advancements in Drug structure of Anti-Epileptic Drugs and increasing social awareness about the evolved drug type are likely to drive the growth of global Anti-Epileptic Drugs market in near future.

Furthermore, advancements in medication management and improvement in healthcare services coupled with increasing number of drug approvals across the globe have led to burgeoning market growth of Anti-Epileptic Drugs market.

Valporic Acid drug segment is expected to dominate global Anti-Epileptic Drugs market during the forecast period. In 2018, Almost half of the market share was held by Valporic Acid drug in the component segment. However, the highest growth rate is expected to be witnessed by the Lacosamide component segment during the forecast period owing to increase in usage in in the treatment of partial-onset seizures.

Request for Sample Report – https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/sample-request

“Major Players are focussing on implementation of healthcare services and also making the drug structure more homogenous to keep leadership in the competitive Anti-Epileptic Drugs market. For example, On January 2017, Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC.”–—GMI Research

Based on geography, North America held the largest share in the market in 2018 because of rising awareness about the disease and treatment available, increase in number of rehabs and surgical centers in the region and exponential increase in the population regarding anti-epileptic drugs. In addition, there has been a rise in the number of approved anti- epileptic drugs. Asia – Pacific region is expected to have the highest growth rate in the forecast years due to high incidence rate of epilepsy diseases.

Key Market Developments:

In 2018, the Valporic Acid drug type held more than half of the market share.

Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals are the leading players holding around one third of the market share.

Lacosamide drug type is anticipated to grow at the highest rate during the forecast period from 2019 to 2026.

Broad Spectrum is the emerging spectrum segment in the Anti-Epileptic Drugs field, which is intended to cater to the unmet needs of the Anti-Epileptic Drugs market.

North America region occupied maximum revenue share in global Anti-Epileptic Drugs market in 2018.

Some of the key players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The Global Anti-Epileptic Drugs Market has been segmented on the basis of spectrum type, the market comprises of Narrow and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide.

For more details, browse the Table of Contents: https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/

Early buyers will get customization upto 20% on report

About GMI Research

Media Contact

Company Name: GMI RESEARCH Contact Person: Media Relations Phone: +353 1 442 8820 Address:Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate City: Dublin State: Dublin Country: Ireland Website: www.gmiresearch.com

0 notes

marketresearchandconsultant-blog · 5 years ago

Text

Epilepsy Drugs Market to Flourish with an Impressive CAGR During 2021

Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.

Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.

Request for a sample of report @

https://mindaspiremarketresearch.com/request-sample/report/epilepsy-drugs-market

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

The research report titled “Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021” examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market

Key Topics Covered in the Report

• Worldwide Epilepsy Drugs Market Analysis (2013 – 2021)

• Worldwide Epilepsy Drugs Market Share (2013 – 2021)

• Worldwide Epilepsy Drugs Brand Market Performance (2013 – 2021)

• Epilepsy Drugs Market – Major Deal Types

• Key Companies Analysis

• Key Drivers and Inhibitors of the Epilepsy Drugs Market

Key Epilepsy Drugs Covered in the Report are as follows:

1. Vimpat(Lacosamide)

2. Keppra(Levetiracetam)

3. Briviact(Brivaracetam)

4. Lamictal(Lamotrigine)

5. Neurontin (Gabapentin)

6. Depakine (Sodium Valproate)

7. Sabril (Vigabatrin)

8. Onfi(Clobazam)

9. Fycompa(Perampanel)

10. Inovelon/Banzel(Rufinamide)

11. Zonegran (Zonisamide)

12. Zebinix (Eslicarbazepine Acetate)

Ask an Analyst @

https://mindaspiremarketresearch.com/inquire/report/epilepsy-drugs-market

Key Companies Covered in the Report are as follows:

1. UCB

2. EISAI

3. Pfizer

4. Sanofi

5. Lundbeck

#Epilepsy Drugs Market

0 notes

theshadowytastemakerstuden-blog1 · 6 years ago

Text

Epilepsy Drugs Market : Growth, Demand, Supply, SWOT, Consumption, ROI to 2025

Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types – generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025.

Epilepsy can develop in both males and females of all races, ethnic backgrounds and ages. It affects around 65 Million people globally. United States has around 3.4 Million epilepsy patients; among them around 470 Thousands are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.

Request to view sample copy for Technical & Professional Industry Insights at: https://www.researchmoz.us/enquiry.php?type=S&repid=2097342

The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in United States will also help in the growth of Epilepsy drug market during the forecast period as well.

Renub Research report titled “Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan), Drugs [(Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)], Treatment Drugs Generation (First, Second, Third), Company (Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.) & Forecast” provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

Read Report Overview of Report @ https://www.researchmoz.us/epilepsy-drugs-market-by-country-us-uk-france-etc-drugs-vimpat-keppra-sabril-onfi-etc-treatment-drugs-generation-first-second-third-companies-forecast-report.html

By Country – United States is Dominating Global Epilepsy Drugs Market

The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan. United States is dominating global epilepsy drugs market. Its share is expected to grow in the years to come due to better healthcare support system, growing awareness and increasing per capita healthcare expenditure.

By Drugs – Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role

The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing the significant role for the epilepsy treatment. Epidiolex has a bright future ahead.

By Drugs Category – Second and Third Generation Plays the Significant Role

In this report, we have categorized the epilepsy drugs market into three generation; First Generation, Second Generation, Third Generation. It is anticipated that second and third generation plays the significant role in the global epilepsy drugs market during the forecast period of 2019-2025.

Company Analysis

Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.

Countries covered in this report are:

United States

United Kingdom

France

Germany

Italy

Spain

India

China

Japan

Epilepsy Drugs Category – By Generation

First Generation

Second Generation

Third Generation

Drugs covered in this report are:

Vimpat (Lacosamide)

Keppra (Levetiracetam)

Sabril (Vigabatrin)

Onfi (Clobazam)

Fycompa

Briviact (Brivaracetam)

Epidiolex

Cenobamate (YKP3089)

Companies covered in this report are:

Eisai Co., Ltd

UCB Inc.

H. Lundbeck A/S

GW Pharmaceuticals Plc.

About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact: ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Website: https://www.researchmoz.us Email: [email protected] Follow us on LinkedIn @ http://bit.ly/1TBmnVG Blog: https://researchknowledgeresource.blogspot.com/

0 notes

go-gmiresearch-blog · 6 years ago

Text

Global Anti-Epileptic Drugs Market Opportunities & Forecast (2018-2025)-GMI Research

Global Anti-Epileptic Drugs Market, By Spectrum Type (Narrow Spectrum and Broad Spectrum), By Drug (Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide) and Geography – Opportunities & Forecast, 2018-2025

The global Anti-Epileptic Drugs market was valued at USD 3,323.7 million in 2017 and is projected to reach USD 4,458.1 million by 2025, growing at a CAGR of 3.8% during 2018–2025.

Figure 1: Global Anti-Epileptic Drugs Market Revenue, 2018–2025 (USD Million) Source: GMI Research

The antiepileptic drug can also be known as an anti-seizure drug, developed for the asymptomatic and idiopathic treatment of epilepsy and seizures. Antiepileptic drugs can also be used for the treatment of neuropathic pain. Causes of epilepsy seizures are not defined or undetermined. However major factors involved include brain injury, stroke, and substance use disorders. Treatment of epilepsy, antiepileptic drugs or medicines (AEDs) are prescribed, preference is made depending on the age of the patient, type of seizures to be treated, and which part of the brain is involved. Moreover, alcoholism, smoking, dietary habits, and rising geriatric population are the major factor driving the antiepileptic drugs market.

Request Sample Brochure : https://tinyurl.com/y776x8ar

Based on Drugs, Valproic Acid (salt) is anticipated to lead the market during 2018–2025 The valporic Acid segment is expected to hold maximum share in the market during the forecast period due to effective drug structure and usage in most type of seizures. However, the highest growth rate is predicted to be exhibited by Lacosamide drug during the forecast period owing to surging adoption of Anti-Epileptic Drugs market among healthcare professionals and patients due to its homogenous structure. Additionally, the wide availability of technically advanced Anti-Epileptic Drugs diagnosis and treatment and rising demand for home-based Anti-Epileptic Drugs treatment are likely to push the growth of global Anti-Epileptic Drugs market in the forecast years.

Figure 2: Global Anti-Epileptic Drugs Market Revenue, by Region, 2017 Source: GMI Research

North America held the largest share in the global Anti-Epileptic Drugs market in 2017 owing to the growing social awareness, social acceptance, awareness among the population and government and private inclination on Anti-Epileptic Drugs issues. Rest of the World is predicted to be the attractive regional market in global Anti-Epileptic Drugs market and is likely to show the maximum growth in the next few years.

The global Anti-Epileptic Drugs market has been segmented on the basis of spectrum type, drug type, and key geographies. Based on spectrum type, the market comprises of Narrow Spectrum and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide

The research report “global Anti-Epileptic Drugs market” provides in-depth analysis of the Anti-Epileptic Drugs market, globally, based on spectrum type, drug type and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers propelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for Anti-Epileptic Drugs market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

Key questions answered in this research report: 1- At what pace is the Anti-Epileptic Drugs market growing worldwide? What will be the growth trend in the future? 2- What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the coming years? 3- What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in global Anti-Epileptic Drugs market? 4- What are the various application areas and how they are poised to grow?

For Sample Pages & Detailed Report Description Click @ https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-opportunities-forecast-by-spectrum-type-share-trends-industry-report.html

Table of Contents (TOC)

1. Executive Summary

2. Introduction 2.1. Study Objectives 2.2. Market Definition 2.2.1. Market Covered 2.2.2. Geographical Coverage 2.2.3. Study Years & Currency 2.3. Market Stakeholders 2.4. Key Questions this Study will Answer 2.5. GMI Research’s Approach & Methodology

3. Global Anti-Epileptic Drugs Market – Overview 3.1. Introduction ` 3.2. Market Segmentation 3.3. Pipeline Analysis 3.4. Drivers 3.5. Restraints 3.6. Trends 4. Global Anti-Epileptic Drugs Market Revenue Forecast till 2025

5. Global Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 5.1. Narrow Spectrum 5.2. Broad Spectrum 6. Global Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025 6.1. Phenytoin 6.2. Phenobarbital 6.3. Carbamazepine 6.4. Oxcarbazepine 6.5. Gabapentin 6.6. Pregabalin 6.7. Lacosamide 6.8. Vigabatrin 6.9. Valproic Acid 6.10. Lamotrigine 6.11. Topiramate 6.12. Zonisamide 6.13. Levetiracetam 6.14. Clonazepam 6.15. Rufinamide 7. Global Anti-Epileptic Drugs Market by Geography Revenue Forecast till 2025

7.1. North America Anti-Epileptic Drugs Market Revenue Forecast till 2025 (Option 1: 25% customization) 7.1.1. North America Anti-Epileptic Drugs Market Revenue by Spectrum Forecast till 2025 7.1.1.1. Narrow Spectrum 7.1.1.2. Broad Spectrum

7.1.2. North America Anti-Epileptic Drugs Market by drug Revenue Forecast till 2025 7.1.2.1. Phenytoin 7.1.2.2. Phenobarbital 7.1.2.3. Carbamazepine 7.1.2.4. Oxcarbazepine 7.1.2.5. Gabapentin 7.1.2.6. Pregabalin 7.1.2.7. Lacosamide 7.1.2.8. Vigabatrin 7.1.2.9. Valproic Acid 7.1.2.10. Lamotrigine 7.1.2.11. Topiramate 7.1.2.12. Zonisamide 7.1.2.13. Levetiracetam 7.1.2.14. Clonazepam 7.1.2.15. Rufinamide.

7.2. Europe Anti-Epileptic Drugs Market Revenue Forecast till 2025 7.2.1. Europe Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 (Option 2: 25% customization) 7.2.1.1. Narrow Spectrum 7.2.1.2. Broad Spectrum

7.2.2. Europe Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025 7.2.2.1. Phenytoin 7.2.2.2. Phenobarbital 7.2.2.3. Carbamazepine 7.2.2.4. Oxcarbazepine 7.2.2.5. Gabapentin 7.2.2.6. Pregabalin 7.2.2.7. Lacosamide 7.2.2.8. Vigabatrin 7.2.2.9. Valproic Acid 7.2.2.10. Lamotrigine 7.2.2.11. Topiramate 7.2.2.12. Zonisamide 7.2.2.13. Levetiracetam 7.2.2.14. Clonazepam 7.2.2.15. Rufinamide.

7.3. Asia-Pacific Anti-Epileptic Drugs Market Revenue Forecast till 2025 7.3.1. Asia-Pacific Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 (Option 3: 25% customization) 7.3.1.1. Narrow Spectrum 7.3.1.2. Broad Spectrum

7.3.2. Asia-Pacific Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025 7.3.2.1. Phenytoin 7.3.2.2. Phenobarbital 7.3.2.3. Carbamazepine 7.3.2.4. Oxcarbazepine 7.3.2.5. Gabapentin 7.3.2.6. Pregabalin 7.3.2.7. Lacosamide 7.3.2.8. Vigabatrin 7.3.2.9. Valproic Acid 7.3.2.10. Lamotrigine 7.3.2.11. Topiramate 7.3.2.12. Zonisamide 7.3.2.13. Levetiracetam 7.3.2.14. Clonazepam 7.3.2.15. Rufinamide.

7.4. Rest of the World Anti-Epileptic Drugs Market Revenue Forecast till 2025 7.4.1. Rest of the World Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 (Option 4: 25% customization) 7.4.1.1. Narrow Spectrum 7.4.1.2. Broad Spectrum

7.4.2. Rest of the World Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025 7.4.2.1. Phenytoin 7.4.2.2. Phenobarbital 7.4.2.3. Carbamazepine 7.4.2.4. Oxcarbazepine 7.4.2.5. Gabapentin 7.4.2.6. Pregabalin 7.4.2.7. Lacosamide 7.4.2.8. Vigabatrin 7.4.2.9. Valproic Acid 7.4.2.10. Lamotrigine 7.4.2.11. Topiramate 7.4.2.12. Zonisamide 7.4.2.13. Levetiracetam 7.4.2.14. Clonazepam 7.4.2.15. Rufinamide.

8. Competitive Landscape 8.1. Industry Attractiveness 8.2. Porter 5 Analysis 8.3. Major players and their key strategies 8.4. Company Share Analysis

9. Company Profiles (Option 5: 25% Customization – Profiles of 5 Additional Companies of your Choice) 9.1. Abbott Laboratories 9.1.1. Company Overview 9.1.2. Financials 9.1.3. Recent Developments 9.2. Cephalon, Inc 9.2.1. Company Overview 9.2.2. Financials 9.2.3. Recent Developments 9.3. Sunovion Pharmaceuticals 9.3.1. Company Overview 9.3.2. Financials 9.3.3. Recent Developments 9.4. Valeant Pharmaceuticals International 9.4.1. Company Overview 9.4.2. Financials 9.4.3. Recent Developments 9.5. Sanofi S.A 9.5.1. Company Overview 9.5.2. Financials 9.5.3. Recent Developments 9.6. UCB Pharma Ltd 9.6.1. Company Overview 9.6.2. Financials 9.6.3. Recent Developments 9.7. GlaxoSmithKline plc 9.7.1. Company Overview 9.7.2. Financials 9.7.3. Recent Developments 9.8. Johnson & Johnson 9.8.1. Company Overview 9.8.2. Financials 9.8.3. Recent Developments 9.9. Novartis AG 9.9.1. Company Overview 9.9.2. Financials 9.9.3. Recent Developments 9.10. Pfizer Inc 9.10.1. Company Overview 9.10.2. Financials 9.10.3. Recent Developments

10. About GMI Research

Buy Report @ https://tinyurl.com/y776x8ar

Related Report :

Global Drugs of Abuse Testing Market by Product Type (Instruments and Consumables), By Drug Type (Psychostimulants, Narcotic, Hallucinogens, Sedatives and Others), By Technique Type (Immunoassay, Chromatography and Rapid Testing), By End-User (Hospitals, Diagnostic Laboratories, Forensic Laboratories, Government and Private Departments and Others) and by Geography – Opportunities & Forecast, 2018-2025

About US

GMI Research leverages its industry expertise and experience to identify the industry trends, big opportunities and potential growth areas across industries. Our Syndicated reports provide actionable insights and covers industry trends, market drivers & restraints, macroeconomics factors, market estimates & forecasts, competitive landscape etc. which helps our clients to strengthen its market position by deploying specific strategies and actions that will lead to higher growth.

Our Customized Research (Market Intelligence and Competitive Intelligence) Offerings

Our clients rely on us for the range of our services to give them the intelligence they need to act decisively. GMI Research offers in-depth market and competitive intelligence solutions by leveraging its industry knowledge and experience to provide accurate insights with a complete picture of the market and competition. To know more about our product offering click on the below link:https://www.gmiresearch.com/productservices/marketcompetitiveintelligence.html

Our Company Profile Solution

Company Profiles provide an insight on competitors, customers, and potential suppliers. We at GMI Research understands that the standard or on shelf company profiles provides little help when it comes to business decision making as it doesn’t cover the information required by the clients.

We have developed a range of company profiles solution to meet our client’s specific business requirements irrespective of their role and the industry they operate in. Our company profiles solutions fit into our client’s business requirements because it provides our client’s with a broader choice of profiles: https://www.gmiresearch.com/productservices/companyprofiles.html

Contact – Sarah Nash

Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate, Dublin D18 Y3X2, Ireland

U.S Office +1 860 881 2270 Europe Office +353 1 442 8820

Email: [email protected]

#global anti epileptic drugs market #Narrow Spectrum #Broad Spectrum #anti-epileptic drugs #gmi research

0 notes

medicaldevicetech · 4 years ago

Text

Analysis On Post-operative Pain Management Market Size, Share, Research Report

Post-operative Pain Management Market Analysis

Get Latest Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1246

Market Segmentation

The MRFR report provides an all-inclusive segmental analysis of the Post Operative Pain Management Market Growth on the basis of target area, application, product, and pain type.

Based on pain type, the post-operative pain management market is segmented into severe pain, moderate pain, and acute pain.

Based on the product, the post-operative pain management market is segmented into opioids, COX-2 inhibitors, antiepileptic drugs, non-steroidal anti-inflammatory drugs, and other analgesics.

Based on target area, the global post-operative pain management market is segmented into arms, hand, legs, back, and others.

Regional Analysis

Key Players

Industry News

August 2019: Dr. Reddy’s Laboratories has recently launched generic anti-epileptic Vigabatrin powder in the US market for oral solution.

Read more @ https://www.marketresearchfuture.com/reports/post-operative-pain-management-market-1246

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India +1 646 845 9312 Email: [email protected]

#Post-operative Pain Management Market Analysis

0 notes

healthcarepharma-blog · 7 years ago

Text

Global Epilepsy Drugs Market - Positive Long-Term Growth Outlook 2017-2021

September Offer -

Flat 20% discount on purchase of this report from 15th to 30th September @ https://www.researchtrades.com/discount/1242108

For more offers post 30th September, kindly contact us.

Contact No. : +16269994607 (US)/ +91 7507349866 (IND)

Email: [email protected]

Report Overview:

The “Global Epilepsy Drugs Market Research Report” is a professional and in-depth study on the current state of the Epilepsy Drugs Market. The study offers an insight into current and future market trends, key drivers and restraints, market strategies of key market players along with detailed segmentation and forecast. The study offers industry overview by covering basic aspects such as product definition and classification, market size and share of segments and sub-segments. This report offers market insights into the changing dynamics by analysis the elements of industry chain structure, key marketing channels and the innovative strategies adopted by key market players to gain a competitive advantage in the market.

Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.

Get Exclusive sample copy @ https://www.researchtrades.com/request-sample/1242108

The research report titled- Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021- examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.

Key Topics Covered in the Report

1. Worldwide Epilepsy Drugs Market Analysis (2013 -2021)

2. Worldwide Epilepsy Drugs Market Share (2013 -2021)

3. Worldwide Epilepsy Drugs Brand Market Performance (2013- 2021)

4. Epilepsy Drugs Market- Major Deal Types

5. Key Companies Analysis

6. Key Drivers and Inhibitors of the Epilepsy Drugs Market

Key Epilepsy Drugs Covered in the Report is as follows:

1. Vimpat (Lacosamide)

2. Keppra (Levetiracetam)

3. Briviact (Brivaracetam)

4. Lamictal (Lamotrigine)

5. Neurontin (Gabapentin)

6. Depakine (Sodium Valproate)

7. Sabril (Vigabatrin)

8. Onfi (Clobazam)

9. Fycompa (Perampanel)

10. Inovelon/Banzel (Rufinamide)

11. Zonegran (Zonisamide)

12. Zebinix (Eslicarbazepine Acetate)

Key Companies Covered in the Report is as follows:

1. UCB

2. EISAI

3. Pfizer

4. Sanofi

5. Lundbeck

….

Browse This Report @ https://www.researchtrades.com/report/epilepsy-drugs-market-global-demand-growth-potential-opportunity-outlook-2021/1242108

Who we are

Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

#Research Trades #Global Epilepsy Drugs Market Share #Global Epilepsy Drugs Market Size #Global Epilepsy Drugs Market

0 notes

nikitamanwar · 5 years ago

Text

Global Anti-Epileptic Drugs Market to be Worth Nearly US$ 4,458.0 Million by 2027 - GMI Research

GMI Research has published a new study titled “Global Anti-Epileptic Drugs Market, By Spectrum Type (Narrow Spectrum and Broad Spectrum), By Drug (Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide) and Geography – Opportunities & Forecast, 2019-2026”, which orates the future prospects set to strike the Anti-Epileptic Drugs Market during the forecast period.

The Global Anti-Epileptic Drugs Market was valued at USD 3,323.7 million in 2018, and is projected to reach USD 4,458.0 million by 2026, growing at a CAGR of 3.8% during 2019-2026. Alcoholism, smoking, Dietary habits and rising geriatric population are the major factor driving the antiepileptic drugs market. Additionally, wide availability of technically advanced Anti-Epileptic Drugs, improvement in diagnosis and treatment of epilepsy and rising demand for home based Anti-Epileptic Drugs treatment are likely to push the growth of global Anti-Epileptic Drugs market in the forecast years.

Get Report Sample Copy @ https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/sample-request

Request Customization @ https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/request-for-customization

Market Segmentation By Spectrum type • arrow Spectrum • Broad Spectrum

By Drug • Phenytoin • Phenobarbital • Carbamazepine • Oxcarbazepine • Gabapentin • Pregabalin • Lacosamide • Vigabatrin • Valproic Acid • Lamotrigine • Topiramate • Zonisamide • Levetiracetam • Clonazepam • Rufinamide

By Geography • North America o By Spectrum type o By Drug Type o US o Canada o Mexico

• Europe o By Spectrum type o By Drug Type o UK o Germany o Spain o Rest of Europe

• Asia-Pacific o By Spectrum type o By Drug Type o China o Australia o India o Rest of APAC

• ROW o By Spectrum type o By Drug Type o Brazil o South Africa o GCC countries o Rest of world (remaining countries of the LAMEA region)

For Additional Insights Click to Access Complete Report – https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/

About GMI Research

Media Contact Company Name: GMI RESEARCH Contact Person: Media Relations Email: Send Email Phone: +353 1 442 8820 Address:Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate City: Dublin State: Dublin Country: Ireland Website: www.gmiresearch.com

0 notes

nikitamanwar · 5 years ago

Text

GLOBAL ANTI-EPILEPTIC DRUGS MARKET ESTIMATED TO SOAR HIGHER DURING 2019 TO 2026